Stockscreener 앱 받기
1.19
0.83%
-0.01
시간 외 거래:
1.23
0.04
+3.36%
전일 마감가:
$1.20
열려 있는:
$1.24
하루 거래량:
60,471
Relative Volume:
0.38
시가총액:
$31.28M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.83%
1개월 성능:
+4.39%
6개월 성능:
-10.53%
1년 성능:
-41.67%
1일 변동 폭
$1.15
$1.27
1주일 범위
$1.09
$1.28
52주 변동 폭
$1.02
$2.40
Rein Therapeutics Inc Stock (RNTX) Company Profile
명칭
Rein Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.19 | 31.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
Rein Therapeutics Inc 주식(RNTX)의 최신 뉴스
With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients - Pulmonary Fibrosis News
Rein Therapeutics doses first patient in IPF trial for LTI-03 - Investing.com Canada
Rein Therapeutics doses first patient in phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis - marketscreener.com
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - GlobeNewswire
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView
Chet Holmgren x Nike KD 18 "Thunder & Reign" Releases March 13th - Sneaker Bar Detroit
RNTX Technical Analysis & Stock Price Forecast - Intellectia AI
Rein Therapeutics Inc. announced that it has received $2.3 million in funding - marketscreener.com
White House to host Big Tech after pledge to rein in power costs - Yahoo Finance
Profit Recap: What are the future prospects of Sage Therapeutics Inc2025 Analyst Calls & Daily Entry Point Trade Alerts - baoquankhu1.vn
Rein Therapeutics Inc. announced that it expects to receive $2.3 million in funding - marketscreener.com
Targets Report: What makes Rein Therapeutics Inc stock attractive today2025 Technical Patterns & Smart Swing Trading Alerts - baoquankhu1.vn
Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks
Rein Therapeutics (RNTX) director Aivado resigns from board role - Stock Titan
Quarterly Recap: How cyclical is The Nassau Companies of New York Preferred Securitys revenue streamEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rein Therapeutics Inc. Announces Manuel C. Alves Aivado Decides to Resign as Member of Board of Directors, Effective February 16, 2026 - marketscreener.com
Will Rein Therapeutics Inc. stock split again soon2025 Support & Resistance & Consistent Profit Trading Strategies - mfd.ru
Is Meteoric Resources NL (RNF) stock a buy for dividend portfoliosLayoff News & Verified Momentum Watchlists - mfd.ru
Stock Report: How correlated is Madrigal Pharmaceuticals Inc to the S P500Weekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Why Sterling Infrastructure Inc. (UAO) stock appeals to dividend investors2025 Market Outlook & Free Fast Entry Momentum Trade Alerts - mfd.ru
Is Rein Therapeutics Inc. stock oversold or undervalued2025 Price Action Summary & Daily Stock Trend Watchlist - mfd.ru
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - The Manila Times
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire
Buy Signal: What is Sotera Health Companys valuation compared to sectorJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
Rein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20 - Nasdaq
Aug Sentiment: Is Rein Therapeutics Inc a speculative investmentJuly 2025 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 76.0% in January - Defense World
KDA Group (CVE:KDA) Stock Price Up 23.5% – Still a Buy? - Defense World
Pinewood Technologies Group (LON:PINE) Shares Up 22.4% – What’s Next? - Defense World
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jones Trading initiates coverage on Rein Therapeutics stock with Buy rating - Investing.com Canada
Introducing Rein Security: Bringing Production Context to Application Security - Yahoo Finance
Smart Money: Can ASAN sustain earnings growthJuly 2025 Action & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Buy Signal: Is Rein Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Rally Mode: What is the target price for Inno Holdings Inc stockBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
Inhaled IPF therapy LTI-03 awarded orphan drug status in Europe - Pulmonary Fibrosis News
RNTX: Analyst Downgrade by Brookline Capital to 'Hold' | RNTX St - GuruFocus
Brookline Capital Downgrades Rein Therapeutics(RNTX.US) to Hold Rating - 富途牛牛
Rein Therapeutics receives EMA orphan drug designation for IPF treatment By Investing.com - Investing.com Canada
Effort to rein in Wall Street landlords could push US home prices up, investors say - Yahoo Finance
Growth Report: Should I invest in LGCY before earningsTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis - The Manila Times
NN, Inc. Appoints Ted White to Board of Directors - manilatimes.net
Corteva Agriscience Unveils Telbek™ PRO: First Group 21 Fungicide in Cereals, Tackling Fusarium Head Blight for Canadian Wheat Growers - The Manila Times
Titan Aviation Leasing Acquires Boeing 777-300ER to Support China Airlines’ Long-Haul Growth - The Manila Times
Fusemachines Announces Additional Investment by Existing Investor to Support Product Expansion and Client Growth - manilatimes.net
Rein Therapeutics Receives Orphan Drug Designation from - GlobeNewswire
Form 8-KMaterial Events - Stock Titan
Can Rein Therapeutics Inc. stock beat market expectations this quarterSector Performance Drivers & Maximum Profit Growth - bollywoodhelpline.com
Rein Therapeutics Inc (RNTX) 재무 분석
Rein Therapeutics Inc (RNTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):